Home Duke University Press
QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Journal of Health Politics, Policy and Law 2008 33(2):325-327; DOI:10.1215/03616878-2007-064
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Light, D. W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Commentary

Reply to DiMasi, Hansen, and Grabowski

Donald W. Light
University of Medicine and Dentistry of New Jersey University of Pennsylvania

Besides critiquing the Congressional Budget Office for failing to cite and discuss evidence from independent sources that suggest that the net corporate costs of pharmaceutical research and development costs are much lower than industry advocates claim, Light's review showed how these high estimates are constructed realities that one can reconstruct by using different assumptions, data, or calculations and come up with much lower estimates. In their reply here, DiMasi, Hansen, and Grabowski unwittingly reinforce that point.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2008 by Duke University Press